X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MRT-8102 is a first-in-class NEK7 directed molecular glue degrader and NLRP3/IL-1β pathway inhibitor, which is being evaluated for the treatment of multiple inflammatory diseases, including gout, pericarditis and other cardiovascular diseases.
Lead Product(s): MRT-8102
Therapeutic Area: Rheumatology Product Name: MRT-8102
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Monte Rosa intends to use the proceeds towards the advancement of its clinical and late preclinical pipeline, including MRT-2359, its orally bioavailable, GSPT1-directed MGD, MRT-6160, its orally bioavailable VAV1-directed MGD, and its NEK7 program.
Lead Product(s): MRT-2359
Therapeutic Area: Oncology Product Name: MRT-2359
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 26, 2023
Details:
The collaboration aims to discover and develop MGDs, small molecule protein degraders, against targets in cancer and neurological diseases previously considered impossible to drug by using Monte Rosa Therapeutics’ highly differentiated QuEENTM discovery engine.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $2,050.0 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement October 17, 2023
Details:
MRT-2359 is a orally bioavailable investigational molecular glue degrader (MGD) that induces the interaction between the E3 ubiquitin ligase component cereblon and the translation termination factor GSPT1, leading to the targeted degradation of GSPT1 protein.
Lead Product(s): MRT-2359
Therapeutic Area: Oncology Product Name: MRT-2359
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
MRT-6160 is a potent, highly selective, and orally bioavailable degrader of VAV1, which has shown deep degradation of its target with no detectable effects on other proteins.
Lead Product(s): MRT-6160
Therapeutic Area: Immunology Product Name: MRT-6160
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
MRT-2359 is a potent, selective and orally bioavailable molecular glue degrader (MGD) that induces the interaction between the E3 ubiquitin ligase component cereblon (CRBN) and the translation termination factor GSPT1, leading to the targeted degradation of GSPT1 protein.
Lead Product(s): MRT-2359
Therapeutic Area: Oncology Product Name: MRT-2359
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
MRT-2359 is a potent, selective and orally bioavailable molecular glue degrader (MGD) that induces the interaction between the E3 ubiquitin ligase component cereblon (CRBN) and the translation termination factor GSPT1, leading to the targeted degradation of GSPT1 protein. T
Lead Product(s): MRT-2359
Therapeutic Area: Oncology Product Name: MRT-2359
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
MRT-2359 induces degradation of GSPT1 and associated downregulation of N-Myc and its transcriptional output, leading to preferential anti-proliferative activity in lung cancer cell lines with high L-Myc and N-Myc mRNA expression.
Lead Product(s): MRT-2359
Therapeutic Area: Oncology Product Name: MRT-2359
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
MRT-048 solidifies GSPT1 as a critical target and has inspired our discovery and development of novel orally available and highly selective GSPT1-directed molecular glue degraders with activity in solid and liquid tumors.
Lead Product(s): MRT-048
Therapeutic Area: Oncology Product Name: MRT-048
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
MRT-048, has demonstrated a differentiated degradation profile and promising in vivo activity in several models of resistant breast cancer. MRT-048 is GSPT1-directed molecular glue degrader targeting Myc-driven breast cancer.
Lead Product(s): MRT-048
Therapeutic Area: Oncology Product Name: MRT-048
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Research UK Cancer Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
